

# Jung Yong Hong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7833770/publications.pdf>

Version: 2024-02-01

108  
papers

1,591  
citations

448610

19  
h-index

445137

33  
g-index

113  
all docs

113  
docs citations

113  
times ranked

2793  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. <i>European Radiology</i> , 2022, 32, 1-11.	2.3	6
2	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
3	Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. <i>Gastroenterology</i> , 2022, 162, 509-520.e7.	0.6	23
4	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	1.9	39
5	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 894-906.	1.3	6
6	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
7	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial. <i>Journal of Cancer</i> , 2022, 13, 1097-1102.	1.2	2
8	Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 415-415.	0.8	3
9	Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/ nab</i>-paclitaxel.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS632-TPS632.	0.8	2
10	Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 163, 119-127.	1.3	12
11	Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 551-551.	0.8	0
12	A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.. <i>Journal of Clinical Oncology</i> , 2022, 40, 494-494.	0.8	1
13	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	7
14	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
15	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
16	Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3623-3632.	0.8	3
17	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	10
18	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/ nab</i>-paclitaxel.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16299-e16299.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4045-4045.	0.8	0
20	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	2.7	34
21	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1593-1603.	2.0	32
22	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	0.9	6
23	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	1.2	4
24	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. <i>Journal of Cancer</i> , 2021, 12, 5681-5686.	1.2	0
25	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€“High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	7.7	105
26	Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 4241-4250.	0.9	3
27	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
28	Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study. <i>European Journal of Cancer</i> , 2021, 150, 73-82.	1.3	15
29	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 701668.	2.2	13
30	Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210352.	1.0	7
31	Reducing tumor invasiveness by ramucirumab and TGFâ€“ $\beta$ 2 receptor kinase inhibitor in a diffuseâ€“type gastric cancer patientâ€“derived cell model. <i>Cancer Medicine</i> , 2021, 10, 7253-7262.	1.3	10
32	Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study. <i>European Journal of Cancer</i> , 2021, 155, 97-105.	1.3	5
33	Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154848.	1.5	16
34	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. <i>In Vivo</i> , 2021, 35, 499-505.	0.6	1
35	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
36	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	3.6	17

#	ARTICLE	IF	CITATIONS
37	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	10
38	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2021, 13, 59.	1.7	8
39	How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. <i>Journal of Cancer Education</i> , 2020, 35, 545-556.	0.6	1
40	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	0.8	3
41	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2020, 61, 1119-1125.	0.6	5
42	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020, 15, 67-73.	1.7	1
43	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 152, 19-25.	0.3	9
44	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	1.4	9
45	Obesity Has a Stronger Relationship with Colorectal Cancer in Postmenopausal Women than Premenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2277-2288.	1.1	4
46	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	8
47	Regional Lymph Node Metastasis of Scalp Angiosarcoma: A Detailed Clinical Observation Study of 40 Cases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3018-3027.	0.7	8
48	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	0.4	26
49	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	1.9	32
50	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , 2020, 15, 485-493.	1.7	6
51	Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. <i>Scientific Reports</i> , 2020, 10, 10680.	1.6	5
52	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	1.0	6
53	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	7
54	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	3.6	20

#	ARTICLE	IF	CITATIONS
55	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	1.7	5
56	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000670.	2.0	17
57	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i> -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 222-232.	1.5	16
58	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020, 15, 203-209.	1.7	3
59	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152947.	1.0	11
60	A phase I study of TGF- $\beta$ 2 inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11557-11557.	0.8	6
61	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	1.3	26
62	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4624-4624.	0.8	0
63	Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4584-4584.	0.8	5
64	A clinical scoring system for survival prediction in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 436-436.	0.8	0
65	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	7.7	155
66	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	1.1	17
67	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	0.8	43
68	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	0.6	4
69	Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. <i>International Journal of Hematology</i> , 2019, 110, 86-94.	0.7	19
70	A Scoring System for Prediction of Cervical Lymph Node Metastasis in Patients with Head and Neck Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , 2019, 40, 1049-1054.	1.2	30
71	Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 7193.	1.6	17
72	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. <i>PLoS ONE</i> , 2019, 14, e0215080.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1657-1664.	0.8	10
74	Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis. <i>Transfusion</i> , 2019, 59, 1781-1788.	0.8	0
75	Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma. <i>Blood Research</i> , 2019, 54, 285-288.	0.5	5
76	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	1.6	12
77	Prognostic Value of Radiologic Extranodal Extension in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. <i>Korean Journal of Radiology</i> , 2019, 20, 1266.	1.5	20
78	Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1107-1115.	0.7	1
79	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	0.8	16
80	Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea. <i>Acta Haematologica</i> , 2018, 139, 185-192.	0.7	8
81	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	1.2	5
82	Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 462-467.	0.6	8
83	Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. <i>Blood Research</i> , 2018, 53, 189.	0.5	10
84	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. <i>Annals of Hematology</i> , 2018, 97, 1851-1857.	0.8	5
85	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	0.8	13
86	Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 5346-5346.	0.6	1
87	Prognostic Value of Serum Beta-2 Microglobulin during and after Completing Chemotherapy in Marginal Zone Lymphoma. <i>Blood</i> , 2018, 132, 5335-5335.	0.6	0
88	Central Nervous System Relapse in Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2018, 132, 1634-1634.	0.6	0
89	Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	0.8	23
90	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. <i>Blood Research</i> , 2017, 52, 270.	0.5	6

#	ARTICLE	IF	CITATIONS
91	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. <i>Blood Research</i> , 2017, 52, 285.	0.5	19
92	Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF- $\kappa$ B and Btk. <i>Oncotarget</i> , 2017, 8, 5361-5370.	0.8	22
93	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Oncotarget</i> , 2017, 8, 13782-13791.	0.8	17
94	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	0.8	13
95	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	0.8	33
96	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. <i>F1000Research</i> , 2016, 5, 1933.	0.8	8
97	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide Conditioning in Patients with Primary Central Nervous System Lymphoma: A Remarkable Outcome Form Single-Center Experience. <i>Blood</i> , 2016, 128, 3462-3462.	0.6	1
98	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 392-398.	1.1	19
99	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	1.1	10
100	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. <i>Acta Haematologica</i> , 2014, 131, 18-27.	0.7	17
101	Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 125-130.	1.1	103
102	Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing. <i>PLoS ONE</i> , 2013, 8, e69752.	1.1	25
103	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15613-e15613.	0.8	0
104	Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP Chemotherapy. <i>Blood</i> , 2013, 122, 5103-5103.	0.6	0
105	Perceptions of clinical trials in gastrointestinal/hepatobiliary cancer patients: A comprehensive survey in a Korean tertiary hospital.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13094-e13094.	0.8	0
106	Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. <i>Medical Oncology</i> , 2009, 26, 186-192.	1.2	30
107	The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. <i>Medical Oncology</i> , 2009, 26, 287-291.	1.2	56
108	Relapsed Intravascular Large B-cell Lymphoma in the Lungs. <i>The Korean Journal of Hematology</i> , 2008, 43, 113.	0.7	0